Objective To explore the effect of Aidi injection combined with FOLFOX4 chemotherapy regimen in treating hepatocellular carcinoma and the influence on inflammatory factors and hydrogen sulphide in serum.Methods Totally 156 patients of hepatocellular carcinoma from March 2013 to January 2015 were divided into observation group (79 cases) and control group (77 cases).Both groups were given conventional treatment;control group were treated with FOLFOX4 chemotherapy, and treatment group were treated with Aidi injection (60 ml added into 500 ml 5％ glucose or 0.9％ sodiun chloride, on the 1st day to the 15th day, intravenous infusion) combined with FOLFOX4 chemotherapy.There were 28 days in 1 course, the treatment lasted for 4 courses.The effective rate was compared between groups, the levels of interleukin (IL)-2, IL-6, transforming growth factor (TGF)-βt, and hydrogen sulphide in serum before and after treatment were compared between the two groups.Results The total effective rate in observation group was significantly higher than that in control group [57.0％ (45/79) vs 42.9％ (33/77)] (Z =-2.236, P ＜ 0.05).Before treatment, the levels of IL-2, IL-6 and TGF-β1 were not significantly different between groups;the IL-2 in observation group was significantly increased after treatment, and was also significantly higher than that in control group after treatment [(6.2 ±2.0) ng/L vs (3.6 ±0.7), (3.4 ± 1.8) ng/L] (P ＜0.01);the levels of IL-6 and TGF-β1 in observation group were significantly decreased after treatment, and were also significantly lower than those in control group after treatment [(3.3±0.8) pg/Lvs (4.2±1.2), (4.3±1.6) pg/L, (29.4±6.8) μg/Lvs (52.1±20.2), (50.9±18.1).μg/L] (P ＜0.01).Before treatment, the level of hydrogen sulphide in serum was not significantly different between groups, while it was significantly increased after treatment in both observation group [(45.3 ±11.9) μmol/L vs (31.8 ± 9.5) μmol/L] and control group [(38.9 ± 11.5) μmol/L vs (33.4 ± 12.1) μ mol/L](P ＜0.01), moreover, it was significantly different between groups.Conclusion The clinical effect of Aidi injection combined with FOLFOX4 chemotherapy is good, and the levels of inflammatory factors and hydrogen sulphide are significantly improved.%目的 探讨艾迪注射液联合FOLFOX4方案治疗原发性肝细胞癌(HCC)的临床效果及对血清炎性因子与硫化氢水平的影响.方法 纳入山东省滨州市中心医院肿瘤科2013年3月至2015年1月收治的156例HCC患者,按照随机数字分配法分为观察组(79例)和对照组(77例).2组均给予常规基础治疗及FOLFOX4化疗方案治疗(2周1次),观察组在对照组的基础上给予艾迪注射液(60 ml加入5％葡萄糖液或0.9％氯化钠注射液500 ml中,第1～15天静脉滴注),28 d为1个疗程,持续4个疗程.比较2组临床疗效,治疗前后血清白细胞介素(IL)2、IL-6、转化生长因子(TGF) β1及硫化氢水平.结果 观察组总有效率明显高于对照组,差异有统计学意义[57.0％(45/79)比42.9％ (33/77)](Z=-2.236,P＜ 0.05).治疗前2组IL-2、IL-6和TGF-β12组差异均无统计学意义(P＞0.05);观察组治疗后IL-2水平较治疗前明显升高,且高于对照组治疗后[(6.2±2.0) ng/L比(3.6±0.7)、(3.4±1.8) ng/L] (P ＜0.01);观察组治疗后IL-6和TGF-β1水平较治疗前明显降低,且低于对照组治疗后,差异有统计学意义[(3.3±0.8)pg/L比(4.2±1.2)、(4.3±1.6)pg/L,(29.4 ±6.8)μg/L比(52.1±20.2)、(50.9±18.1)μg/L] (P ＜0.01).治疗前观察组和对照组血清硫化氢水平差异无统计学意义(P＞0.05),治疗后观察组和对照组硫化氢水平较治疗前均明显升高[(45.3±11.9) μmol/L比(31.8±9.5) μmol/L,(38.9±11.5) μmol/L比(33.4±12.1)μmol/L],差异有统计学意义(P＜0.01),且观察组明显高于对照组,差异有统计学意义(P＜0.01).结论 艾迪注射液联合FOLFOX4化疗方案治疗HCC效果较好,可明显改善患者体内炎性因子和硫化氢水平.
展开▼
